Article type
Year
Abstract
Objectives: Clinical Practice Guidelines (CPGs) offer the potential for economists to be centrally involved in increasing the cost-effectiveness of health services. The use of economic evidence in CPGs is limited given resistance from professions, paucity of economic evidence, time constraints for decision analytic modelling and lack of policy commitment. The session will explore these issues and identify elements of best practice to assist economists.
Description: Initiatives to integrate economic evidence into CPGs will be reported. Professor Michael Drummond University of York, UK, will report on the National Institute of Clinical Excellence (NICE) experiences for 50 guidelines covering schizophrenia, infection control, preoperative tests, chronic heart failure and multiple sclerosis. Kathryn Antioch, Monash University, Health Economics and Funding Reforms, and Health Advisory Committee, NHMRC will report on some teaching hospitals' experience for over 20 surgical and medical CPGs, including cardiology, respiratory and rehabilitation. These hospitals, with support from Government and universities, have evaluated CPGs using cost-effectiveness evidence and translated such evidence into practice through clinical protocols and pathways.
A panel discussion will address the methodological and practical issues encountered and identify solutions relating to the following challenges:
a. How do we grade the quality of economic evidence?
b. What is the role of decision analytic modeling in CPGs?
c. How do we address evidence that includes a broader range of intermediate health outcomes beyond 'cost per life year gained'? What guidelines are available to evaluate such evidence?
d. How do we scope guidelines early enough to identify the cost-effectiveness issues?
e. How can we set clearer priorities for the economist's involvement in guideline development?
f. How do we estimate the cost impact of CPGs?
Target audience: People involved in integrating economic evidence into CPGs and/or translating such evidence into practice through clinical protocols and pathways.
Style: Discussion workshop
Description: Initiatives to integrate economic evidence into CPGs will be reported. Professor Michael Drummond University of York, UK, will report on the National Institute of Clinical Excellence (NICE) experiences for 50 guidelines covering schizophrenia, infection control, preoperative tests, chronic heart failure and multiple sclerosis. Kathryn Antioch, Monash University, Health Economics and Funding Reforms, and Health Advisory Committee, NHMRC will report on some teaching hospitals' experience for over 20 surgical and medical CPGs, including cardiology, respiratory and rehabilitation. These hospitals, with support from Government and universities, have evaluated CPGs using cost-effectiveness evidence and translated such evidence into practice through clinical protocols and pathways.
A panel discussion will address the methodological and practical issues encountered and identify solutions relating to the following challenges:
a. How do we grade the quality of economic evidence?
b. What is the role of decision analytic modeling in CPGs?
c. How do we address evidence that includes a broader range of intermediate health outcomes beyond 'cost per life year gained'? What guidelines are available to evaluate such evidence?
d. How do we scope guidelines early enough to identify the cost-effectiveness issues?
e. How can we set clearer priorities for the economist's involvement in guideline development?
f. How do we estimate the cost impact of CPGs?
Target audience: People involved in integrating economic evidence into CPGs and/or translating such evidence into practice through clinical protocols and pathways.
Style: Discussion workshop